The Joint shares surge 10.84% intraday as Q4 2025 results beat expectations, transition to franchise model boosts profitability.

The Joint surged 10.84% intraday, driven by Q4 2025 earnings exceeding expectations, a shift to a pure franchise model boosting profitability, and optimistic 2026 financial guidance. The company reported $15.2 million in revenue (+3.1% YoY), $0.07 EPS (beating estimates by $0.03), and $3.6 million adjusted EBITDA (+7.8% YoY). It reduced owned clinics from 135 to 48, achieved a $2.9 million net profit (vs. $5.8M loss in 2024), and outlined 2026 guidance of up to $552 million system sales and $125–135 million adjusted EBITDA, alongside a $5.7 million stock buyback plan.